



Express Mail No.: EV 473 971 577 US

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

Application of: Schwab et al.

Confirmation No.: 7264

Application No.: 09/830,972

Group Art Unit: 1649

Filed: September 24, 2001

Examiner: Kolker, Daniel E.

For: NUCLEOTIDE AND PROTEIN SEQUENCES OF  
NOGO GENES AND METHODS BASED  
THEREON

Attorney Docket No.: 10200-003-999

**FIFTH SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT**  
**UNDER 37 C.F.R. §§ 1.56 AND 1.97**

Mail Stop Amendment  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir:

In accordance with the duty of disclosure imposed by 37 C.F.R. §§ 1.56 and 1.97 to inform the United States Patent and Trademark Office ("USPTO") of all references coming to the attention of each individual associated with the filing or prosecution of the subject application, which are or may be material to the patentability of any claim of the application, Attorneys for Applicants hereby invite the Examiner's attention to references C15-C22 listed on the attached form entitled "List of References Cited by Applicant." Copies of references C15-C22 are submitted herewith.


Identification of the listed references is not meant to be construed as an admission of Applicants or Attorneys for Applicants that such references are available as "prior art" against the subject application.

Applicants respectfully request that the Examiner review the foregoing references and that the references be made of record in the file history of the application.

Pursuant to 37 C.F.R. §1.97(c), since this information disclosure statement is being filed after the mailing date of a first Office Action on the merits, a fee of \$180.00 is believed to be due in connection herewith. Please charge the required fee to Jones Day deposit account no. 50-3013. A duplicate copy of this sheet is enclosed for accounting purposes.

Respectfully submitted,

Date: June 21, 2007

 32,605  
Adriane M. Antler (Reg. No.)  
JONES DAY  
222 East 41<sup>st</sup> Street  
New York, New York 10017-6702  
(212) 326-3939

Enclosure

**LIST OF REFERENCES CITED BY APPLICANT**  
(Use several sheets if necessary)

ATTY. DOCKET NO.

10200-003-999

APPLICATION NO.

09/830,972

APPLICANT

Schwab et al.

FILING DATE

September 24, 2001

ART UNIT

1649

**U.S. PATENT DOCUMENTS**

*EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	PAGES, COLUMNS, LINES, WHERE RELEVANT PASSAGES OR RELEVANT FIGURES APPEAR

**FOREIGN PATENT DOCUMENTS**

	FOREIGN PATENT DOCUMENT COUNTRY CODE, NUMBER, KIND CODE (IF KNOWN)	DATE	NAME	PAGES, COLUMNS, LINES, WHERE RELEVANT PASSAGES OR RELEVANT FIGURES APPEAR	T

**NON PATENT LITERATURE DOCUMENTS**

Examiner Initials		(Include name of the author (in CAPITAL LETTERS), Title, Date, Pertinent Pages, Etc.)	T
	C15	GENESEQ Accession No. AAW58383 (1998)	
	C16	GENESEQ Accession No. AAW53947 (1998)	
	C17	Synthetic Peptides, In: Antibodies A Laboratory Manual, Harlow and Lane (eds.), 1988, Cold Spring Harbor Laboratory Press, p.72-77	
	C18	ETHELL et al., 1993, "Changes in protein expression associated with the developmental transition from permissive to restrictive states of spinal cord repair in embryonic chick," Brain Res. Dev. Brain Res. 76(2):163-9	
	C19	GOLDBERG et al., 2000, "Nogo in nerve regeneration," Nature 403(6768):369-70	
	C20	KEIRSTEAD et al., 1992, "Suppression of the onset of myelination extends the permissive period for the functional repair of embryonic spinal cord," Proc. Natl. Acad. Sci. U. S. A. 89(24):11664-8	
	C21	MCKERRACHER et al., 1994, "Identification of myelin-associated glycoprotein as a major myelin-derived inhibitor of neurite growth," Neuron 13(4):805-11	
	C22	TESSIER-LAVIGNE et al., 2000, "Perspectives: neurobiology. Regeneration in the Nogo zone," Science 287(5454):813-4	

**EXAMINER****DATE CONSIDERED**

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.